Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $137.33 Average Price Target from Analysts

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has received an average recommendation of “Moderate Buy” from the fifteen analysts that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $137.3333.

A number of analysts have recently issued reports on MIRM shares. JPMorgan Chase & Co. boosted their price objective on Mirum Pharmaceuticals from $115.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday, July 2nd. Royal Bank Of Canada decreased their target price on shares of Mirum Pharmaceuticals from $148.00 to $135.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Citigroup reissued an “outperform” rating on shares of Mirum Pharmaceuticals in a research report on Thursday, August 6th. CLSA set a $146.00 price objective on Mirum Pharmaceuticals in a research note on Monday, June 15th. Finally, HC Wainwright dropped their target price on Mirum Pharmaceuticals from $185.00 to $140.00 and set a “buy” rating for the company in a report on Thursday, August 6th.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 1,840 shares of the stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $105.29, for a total transaction of $193,733.60. Following the completion of the transaction, the senior vice president directly owned 1,274 shares in the company, valued at $134,139.46. This represents a 59.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Eric Bjerkholt sold 6,001 shares of Mirum Pharmaceuticals stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $99.90, for a total value of $599,499.90. Following the transaction, the chief financial officer directly owned 36,355 shares of the company’s stock, valued at approximately $3,631,864.50. The trade was a 14.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 93,156 shares of company stock worth $9,763,562 over the last three months. Company insiders own 8.32% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Contravisory Investment Management Inc. increased its holdings in Mirum Pharmaceuticals by 2.3% during the 2nd quarter. Contravisory Investment Management Inc. now owns 4,604 shares of the company’s stock valued at $539,000 after purchasing an additional 103 shares in the last quarter. Faithward Advisors LLC raised its position in Mirum Pharmaceuticals by 0.5% in the 1st quarter. Faithward Advisors LLC now owns 27,467 shares of the company’s stock valued at $2,537,000 after purchasing an additional 126 shares during the last quarter. Janney Montgomery Scott LLC boosted its stake in Mirum Pharmaceuticals by 6.7% in the fourth quarter. Janney Montgomery Scott LLC now owns 3,200 shares of the company’s stock worth $253,000 after purchasing an additional 200 shares in the last quarter. Comerica Bank grew its holdings in shares of Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after purchasing an additional 278 shares during the last quarter. Finally, Osaic Holdings Inc. grew its holdings in shares of Mirum Pharmaceuticals by 46.5% during the second quarter. Osaic Holdings Inc. now owns 1,106 shares of the company’s stock worth $56,000 after purchasing an additional 351 shares during the last quarter.

Mirum Pharmaceuticals Price Performance

NASDAQ MIRM opened at $98.77 on Friday. Mirum Pharmaceuticals has a twelve month low of $63.23 and a twelve month high of $130.00. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.74 and a current ratio of 2.86. The stock has a market capitalization of $6.41 billion, a PE ratio of -6.79 and a beta of 0.52. The stock has a 50-day simple moving average of $110.77 and a 200 day simple moving average of $102.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.The company had revenue of $176.24 million for the quarter, compared to the consensus estimate of $166.33 million. During the same period last year, the firm posted ($0.12) EPS. The company’s revenue was up 37.9% compared to the same quarter last year. Research analysts anticipate that Mirum Pharmaceuticals will post -1.31 EPS for the current year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.